If anything, It has become more serious with a more comprehansive DD being conducted that includes the IP details of ATL1103. This in my mind indicates there may be an offer being considered, formulated and finalised. Otherwise, the Pharma wouldn't have spent additional manpower and time on it.
Looking at the recent deals, I would think that a Phase based upfront payment plus milestone could be on the table.
i.e. Cost of Phase 2 trial plus past cost plus profit payment as upfront, milestone payments, option for next phase, option to license. This will minimise risk for the Pharma at each stage but the Bio tech will require a higher payout too for this type of arrangement.
I actually think there should be concluded one way or another before any concrete funding for Phase 2 is being completed by ANP. To start Phase 2 trial by June,funding needs to be firmed up by Feb/March. That may be the timeframe a pharma may work on if they want in for Phase 2.
JIMO
ANP Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
